These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 14688377)

  • 21. Genotypic inhibitory killer immunoglobulin-like receptor ligand incompatibility enhances the long-term antileukemic effect of unmodified allogeneic hematopoietic stem cell transplantation in patients with myeloid leukemias.
    Beelen DW; Ottinger HD; Ferencik S; Elmaagacli AH; Peceny R; Trenschel R; Grosse-Wilde H
    Blood; 2005 Mar; 105(6):2594-600. PubMed ID: 15536148
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Natural killer-cell activity after human renal transplantation in relation to killer immunoglobulin-like receptors and human leukocyte antigen mismatch.
    Vampa ML; Norman PJ; Burnapp L; Vaughan RW; Sacks SH; Wong W
    Transplantation; 2003 Oct; 76(8):1220-8. PubMed ID: 14578757
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients.
    Curti A; Ruggeri L; D'Addio A; Bontadini A; Dan E; Motta MR; Trabanelli S; Giudice V; Urbani E; Martinelli G; Paolini S; Fruet F; Isidori A; Parisi S; Bandini G; Baccarani M; Velardi A; Lemoli RM
    Blood; 2011 Sep; 118(12):3273-9. PubMed ID: 21791425
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Can we make a better match or mismatch with KIR genotyping?
    Mehta RS; Rezvani K
    Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):106-118. PubMed ID: 27913469
    [TBL] [Abstract][Full Text] [Related]  

  • 25. NK-cell purging of leukemia: superior antitumor effects of NK cells H2 allogeneic to the tumor and augmentation with inhibitory receptor blockade.
    Koh CY; Ortaldo JR; Blazar BR; Bennett M; Murphy WJ
    Blood; 2003 Dec; 102(12):4067-75. PubMed ID: 12893752
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Donor KIR3DL1/3DS1 gene and recipient Bw4 KIR ligand as prognostic markers for outcome in unrelated hematopoietic stem cell transplantation.
    Gagne K; Busson M; Bignon JD; Balère-Appert ML; Loiseau P; Dormoy A; Dubois V; Perrier P; Jollet I; Bois M; Masson D; Moine A; Absi L; Blaise D; Charron D; Raffoux C;
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1366-75. PubMed ID: 19822295
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Natural killer cells in the treatment of high-risk acute leukaemia.
    Locatelli F; Moretta F; Brescia L; Merli P
    Semin Immunol; 2014 Apr; 26(2):173-9. PubMed ID: 24613727
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NK cells expressing inhibitory KIR for non-self-ligands remain tolerant in HLA-matched sibling stem cell transplantation.
    Björklund AT; Schaffer M; Fauriat C; Ringdén O; Remberger M; Hammarstedt C; Barrett AJ; Ljungman P; Ljunggren HG; Malmberg KJ
    Blood; 2010 Apr; 115(13):2686-94. PubMed ID: 20097883
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hierarchy of the human natural killer cell response is determined by class and quantity of inhibitory receptors for self-HLA-B and HLA-C ligands.
    Yu J; Heller G; Chewning J; Kim S; Yokoyama WM; Hsu KC
    J Immunol; 2007 Nov; 179(9):5977-89. PubMed ID: 17947671
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of the inhibitory KIR ligand HLA-Bw4 and HLA-C expression levels in the recognition of leukemic cells by Natural Killer cells.
    Verheyden S; Ferrone S; Mulder A; Claas FH; Schots R; De Moerloose B; Benoit Y; Demanet C
    Cancer Immunol Immunother; 2009 Jun; 58(6):855-65. PubMed ID: 18841361
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HLA-C matching status does not affect rituximab-mediated antibody-dependent cellular cytotoxicity by allogeneic natural killer Cells.
    Machino T; Okoshi Y; Miyake Y; Akatsuka Y; Chiba S
    Immunol Invest; 2012; 41(8):831-46. PubMed ID: 22676066
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of Donor Activating KIR-HLA Ligand-Mediated NK Cell Education Status in Control of Malignancy in Hematopoietic Cell Transplant Recipients.
    Nowak J; Kościńska K; Mika-Witkowska R; Rogatko-Koroś M; Mizia S; Jaskuła E; Polak M; Mordak-Domagała M; Lange J; Gronkowska A; Jędrzejczak WW; Kyrcz-Krzemień S; Markiewicz M; Dzierżak-Mietła M; Tomaszewska A; Nasiłowska-Adamska B; Szczepiński A; Hałaburda K; Hellmann A; Czyż A; Gil L; Komarnicki M; Wachowiak J; Barańska M; Kowalczyk J; Drabko K; Goździk J; Wysoczańska B; Bogunia-Kubik K; Graczyk-Pol E; Witkowska A; Marosz-Rudnicka A; Nestorowicz K; Dziopa J; Szlendak U; Warzocha K; Lange A;
    Biol Blood Marrow Transplant; 2015 May; 21(5):829-39. PubMed ID: 25617806
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low number of donor activating killer immunoglobulin-like receptors (KIR) genes but not KIR-ligand mismatch prevents relapse and improves disease-free survival in leukemia patients after in vivo T-cell depleted unrelated stem cell transplantation.
    Kröger N; Binder T; Zabelina T; Wolschke C; Schieder H; Renges H; Ayuk F; Dahlke J; Eiermann T; Zander A
    Transplantation; 2006 Oct; 82(8):1024-30. PubMed ID: 17060849
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Distribution of immunoglobulin like receptor gene in Han population in China and the impact thereof on the HLA-identical sibling hematopoietic stem cell transplantation].
    Dou LP; DA WM; Zhao DD; Wang C; Lu XC; Kang HY; Yan P; Wang FF; Zhu HY; Li HH; Gao CJ; Yu L
    Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(44):3111-4. PubMed ID: 18269867
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunology. A perfect mismatch.
    Kärre K
    Science; 2002 Mar; 295(5562):2029-31. PubMed ID: 11896262
    [No Abstract]   [Full Text] [Related]  

  • 36. Use of NK cell activity in cure by transplant.
    Leung W
    Br J Haematol; 2011 Oct; 155(1):14-29. PubMed ID: 21812770
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ex vivo expansion of highly purified NK cells for immunotherapy after haploidentical stem cell transplantation in children.
    Koehl U; Esser R; Zimmermann S; Tonn T; Kotchetkov R; Bartling T; Sörensen J; Grüttner HP; Bader P; Seifried E; Martin H; Lang P; Passweg JR; Klingebiel T; Schwabe D
    Klin Padiatr; 2005; 217(6):345-50. PubMed ID: 16307421
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibody-dependent cell-mediated cytotoxicity overcomes NK cell resistance in MLL-rearranged leukemia expressing inhibitory KIR ligands but not activating ligands.
    Chan WK; Kung Sutherland M; Li Y; Zalevsky J; Schell S; Leung W
    Clin Cancer Res; 2012 Nov; 18(22):6296-305. PubMed ID: 23014531
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
    Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
    PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antileukemia activity of a natural killer cell line against human leukemias.
    Yan Y; Steinherz P; Klingemann HG; Dennig D; Childs BH; McGuirk J; O'Reilly RJ
    Clin Cancer Res; 1998 Nov; 4(11):2859-68. PubMed ID: 9829753
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.